Literature DB >> 17578604

[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

T Kowalski1, C Maier, A Reinacher-Schick, U Schlegel.   

Abstract

The platinum derivative oxaliplatin is widely used in colorectal cancer. Its side effects differ from those of the other platinum compounds cisplatin and carboplatin. An acute, painful hyperexcitability syndrome (HES) accompanied by cold induced paresthesia, dysesthesia and myotonia is unique to oxaliplatin, whereas a chronic, peripheral sensory neuropathy (PSN) can be caused by all platinum compounds. It is believed that HES is the result of peripheral nerve hyperexcitability as a consequence of voltage-gated sodium channel dysfunction, which may be caused by calcium level imbalance. Therapeutic options for HES are the administration of calcium and magnesium, the serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine and the thiophosphate amifostine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17578604     DOI: 10.1007/s00482-007-0552-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  29 in total

1.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

Authors:  F Grolleau; L Gamelin; M Boisdron-Celle; B Lapied; M Pelhate; E Gamelin
Journal:  J Neurophysiol       Date:  2001-05       Impact factor: 2.714

Review 2.  Clinical pharmacokinetics of oxaliplatin: a critical review.

Authors:  M A Graham; G F Lockwood; D Greenslade; S Brienza; M Bayssas; E Gamelin
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats.

Authors:  M Hirade; H Yasuda; M Omatsu-Kanbe; R Kikkawa; H Kitasato
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

Review 5.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

6.  Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.

Authors:  Christian Lersch; Renate Schmelz; Florian Eckel; Johannes Erdmann; Martina Mayr; Ewert Schulte-Frohlinde; Stefan Quasthoff; Julian Grosskreutz; Helmuth Adelsberger
Journal:  Clin Colorectal Cancer       Date:  2002-05       Impact factor: 4.481

7.  The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

Authors:  H Adelsberger; S Quasthoff; J Grosskreutz; A Lepier; F Eckel; C Lersch
Journal:  Eur J Pharmacol       Date:  2000-10-06       Impact factor: 4.432

8.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Authors:  Richard G Webster; Keith L Brain; Richard H Wilson; Jean L Grem; Angela Vincent
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

9.  Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.

Authors:  Jean-Philippe Durand; Catherine Brezault; François Goldwasser
Journal:  Anticancer Drugs       Date:  2003-07       Impact factor: 2.248

10.  Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Authors:  Laurence Gamelin; Michele Boisdron-Celle; Remy Delva; Véronique Guérin-Meyer; Norbert Ifrah; Alain Morel; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  4 in total

1.  Attenuation of activity in an endogenous analgesia circuit by ongoing pain in the rat.

Authors:  Luiz F Ferrari; Robert W Gear; Jon D Levine
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

2.  [Procedure for certification of QST laboratories].

Authors:  C Geber; A Scherens; D Pfau; N Nestler; M Zenz; T Tölle; R Baron; R-D Treede; C Maier
Journal:  Schmerz       Date:  2009-02       Impact factor: 1.107

Review 3.  Assessment of neuropathic pain in cancer patients.

Authors:  Deborah T Blumenthal
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 4.  Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels.

Authors:  Daniel C Cook; Peter A Goldstein
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.